{"id":"NCT04676334","sponsor":"pharmaand GmbH","briefTitle":"CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib","officialTitle":"CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-22","primaryCompletion":"2023-03-08","completion":"2023-03-08","firstPosted":"2020-12-21","resultsPosted":"2024-05-07","lastUpdate":"2024-05-07"},"enrollment":34,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Castration-Resistant Prostate Cancer","Ovarian Cancer","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer","Other Solid Tumor"],"interventions":[{"type":"DRUG","name":"Rucaparib","otherNames":["CO-338","Rubraca"]}],"arms":[{"label":"Rucaparib","type":"EXPERIMENTAL"},{"label":"Long-term Follow-up","type":"NO_INTERVENTION"}],"summary":"This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit. Participants in long-term follow-up (LTFU) in a parent study may also enroll in this study for continued data collection, as applicable based on parent study objectives.","primaryOutcome":{"measure":"Number of Participants Experiencing SAEs and AESIs","timeFrame":"From first dose of rucaparib through 28 days after receiving last dose of rucaparib (approximately 20 months)","effectByArm":[{"arm":"Rucaparib","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":25,"countries":["Canada","Israel","Italy","Poland","Russia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":[]}}